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ABSTRACT
Aim To assess the long-term efﬁcacy and tolerability of
both derivatives of mycophenolic acid, mycophenolate
mofetil (MMF) and mycophenolate sodium (MPS), in the
therapy of patients with birdshot chorioretinopathy
(BSCR).
Methods Retrospective analysis of 24 patients
(48 eyes) with BSCR, treated with MMF or MPS with a
follow-up of at least 1 year. The main outcome measures
included control of inﬂammation, steroid-sparing
potential and side effects. Secondary outcome measure
was the development of retinal function during the
therapy measured by best-corrected visual acuity (BCVA),
visual ﬁeld and/or electroretinography (ERG).
Results Twelve patients (50%) were treated with MMF
and 12 patients (50%) with MPS. Control of intraocular
inﬂammation, deﬁned as complete lack of clinical and
angiographic signs of inﬂammatory activity, was achieved
in 16 of 24 patients (67%). The angiographic signs of
activity were signiﬁcantly reduced during the follow-up
(p<0.05). No signiﬁcant difference was found in the
mean BCVA, the visual ﬁeld and the ERG parameters
during the treatment compared with the baseline
(p>0.05). In 20 out of 21 patients (95%) who received
systemic corticosteroids, the corticosteroids could be
tapered to a daily dose of ≤10 mg (rate 0.26/patient-
year). Drug-related side effects occurred in 12 patients
(50%, rate 0.16/patient-year). In four patients (17%), a
therapy switch from MMF to MPS was undertaken due
to gastrointestinal discomfort.
Conclusions Derivatives of mycophenolic acid are
effective and safe drugs for the treatment of BSCR. In
cases with gastrointestinal side effects, a therapy switch
from MMF to MPS should be considered.
INTRODUCTION
Birdshot chorioretinopathy (BSCR) is a form of
chronic bilateral posterior uveitis with progressive
course and poor long-term visual prognosis.1
Characteristic for the disease is the presence of
‘birdshot lesions’, manifesting as hypopigmented
cream-coloured round or oval choroidal lesions,
localised around the optic disc.2 The disease is
strongly associated with the human leucocyte
antigen (HLA)-A29.3 4 Due to its chronic relentless
course, BSCR may lead to severe visual impairment
and even blindness.1 Because of the poor visual
outcome during corticosteroid monotherapy, early
treatment with immunosuppressive agents has been
recommended for the management of patients with
BSCR.5–7
Mycophenolic acid (MPA) is an immunosuppres-
sive agent that selectively inhibits the proliferation
of human T-lymphocytes and B-lymphocytes.8 Both
derivatives of MPA, mycophenolate mofetil (MMF)
and mycophenolate sodium (MPS), have been
shown to be effective for the therapy of chronic
non-infectious uveitis.9–13 To date, only limited data
are available about the use of MMF as a steroid-
sparing agent in the treatment of BSCR.7 14 15 To
the best of our knowledge, the use of MPS in the
treatment of BSCR has not been previously
reported. The aim of this study was to assess the
long-term efﬁcacy and tolerability of both deriva-
tives of MPA, MMF and MPS, in the therapy of
BSCR.
METHODS
Patients
A retrospective analysis was performed including
all patients with BSCR who were treated at our
institution with MMF or MPS and who had a
follow-up of at least 1 year. BSCR was diagnosed
according to the criteria established by an inter-
national consensus panel.2 In all patients, an exten-
sive uveitis work-up was performed to exclude
other diseases that can cause multifocal choroidal
lesions. Additionally, HLA-A29 typing was per-
formed in all patients.
A full ophthalmological examination, including
the assessment of best-corrected visual acuity
(BCVA), tonometry, slit-lamp biomicroscopy and
fundus exam, was performed in all patients.
Additional ophthalmological investigations includ-
ing ﬂuorescein angiography (FA), optical coherence
tomography (OCT), visual ﬁeld and electroretino-
graphy (ERG) were performed in most patients.
Treatment
MMF was administered at a dose of 1000 mg twice
daily, deﬁned as a standard dosage for MMF. MPS
was given at a dose of 720 mg twice daily, deﬁned
as a standard dosage for MPS. Depending on the
activity of intraocular inﬂammation, systemic pred-
nisolone in an initial dosage of 1 mg/kg/days was
administered in 21 patients. Prednisolone was grad-
ually tapered on a weekly basis (in 10 mg steps to
30 mg/days, in 5 mg steps to 20 mg/days, followed
by 2.5 mg steps) to a maintenance dose of ≤10 mg
daily.
Outcome measures
The main outcome measures of the study were (i)
control of inﬂammation, (ii) steroid-sparing
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potential and (iii) long-term side effects during MMF/MPS
treatment. The inﬂammatory cell grade was assessed according
to the recommendations of Nussenblatt et al16 and the
Standardization of Uveitis Nomenclature Working Group
(SUN).17 FA was additionally used to assess disease activity.
Angiographic signs in active disease included hyperﬂuorescence
of the optic disc and retinal vascular leakage.7 The optic disc
hyperﬂuorescence and retinal vascular leakage were graded as
absent (0), mild (1) and strong (2). The presence of cystoid
macular oedema (CMO) was detected by ophthalmoscopy, OCT
or FA. Control of intraocular inﬂammation was deﬁned as com-
plete lack of clinical and angiographic signs of inﬂammatory
activity. A relapse of BSCR was considered in case of active
fundus lesions, an increase of cell grade or angiographic signs of
activity. The MMF/MPS treatment was assessed as ineffective if
one or more of the following ﬁndings were observed: persistent
intraocular inﬂammation, refractive CMO or development of
CMO for the ﬁrst time during therapy. Corticosteroid-sparing
success was deﬁned as inactive inﬂammation after tapering of
prednisolone to ≤10 mg daily, as recommended by the SUN
Working Group.17
The patients were followed up every 3 months.
Treatment-related side effects were assessed in each patient at
each visit by targeted patient history regarding subjective symp-
toms of side effects and monthly laboratory investigations, per-
formed by general physicians, including complete blood count
with differential, liver enzymes and kidney functional tests.
The secondary outcome measure was the development of the
retinal function during the MMF/MPS therapy. Retinal function
was measured by BCVA, visual ﬁeld or full-ﬁeld ERG. BCVA
was assessed in European decimals and converted to logarithm
of minimum angle of resolution (logMAR) for statistical ana-
lysis. According to the SUN recommendations, improvement/
worsening of BCVA was deﬁned as a change (decrease/increase)
of at least 0.3 logMAR (three lines).17 Visual ﬁeld testing was
performed using automated static perimetry within the central
30° visual ﬁeld (Tuebingen Automatic Perimeter, TAP, Oculus
Inc., Germany; or Octopus 101 perimeter, Haag-Streit Inc,
Switzerland). The following data were collected for each visual
ﬁeld test: foveal threshold (ie, central differential luminance sen-
sitivity) in decibels (dB), and occurrence and pattern of visual
ﬁeld defects within the central 30° visual ﬁeld. Change in the
foveal threshold during the treatment in comparison to the
therapy start (baseline) was considered if the foveal threshold
increased or decreased by ≥5 dB. The scotoma extent within
the central 30° visual ﬁeld eccentricity was estimated by count-
ing the locations with absolute or relative visual ﬁeld defects.
Change was considered if a difference of at least 10% was
found in the number of test locations with absolute or relative
visual ﬁeld loss between baseline and follow-up. Full-ﬁeld ERGs
were recorded using DTL ﬁbre electrodes with Espion E2
(Diagnosys LLC) and a ColorDome (Diagnosys LLC) according
to the standards of the International Society for Clinical
Electrophysiology of Vision (ISCEV).18 For this study, ampli-
tudes and implicit times of the dark-adapted 3.0 ERG (com-
bined rod-cone responses) and the light-adapted 30 Hz ﬂicker
responses were evaluated. Change was considered if a difference
of at least 15% was observed in the amplitudes or implicit times
between baseline and follow-up visits.
Statistical methods
The incidence rate per patient-year (PY) was calculated as the
number of events divided by the amount of patient-time at risk.
Statistically signiﬁcant differences were evaluated using the
Fisher’s exact test, sign test, Wilcoxon signed-rank test and
paired t test, as appropriate. p Values less than 0.05 were consid-
ered to be statistically signiﬁcant. The performed data analysis
was explanatory, and the multiple signiﬁcance tests were applied
only for descriptive purposes.
This work adhered to the tenets of the Declaration of
Helsinki, and Institutional Ethics Committee of University of
Tuebingen granted approval with waiver of informed consent
for this retrospective study.
RESULTS
Characteristics of the study population
Twenty-four patients (48 eyes) with BSCR, who were treated
with MMF or MPS and who had a follow-up of at least 1 year,
were included in the study. All patients had bilateral disease and
were HLA-A29 positive. In 12 patients (50%), the treatment
was started with MMF and in 12 patients (50%) with MPS. The
mean follow-up after therapy initiation was 43 months (median
33 months, range 12–106 months). Baseline patient character-
istics, previous treatment and reason for starting mycophenolate
therapy are presented in table 1.
Treatment outcome
Control of intraocular inﬂammation
Control of intraocular inﬂammation was achieved in 16 of 24
patients (67%) during the treatment with standard dosage of
MMF or MPS. In ﬁve of these patients, a relapse of BSCR
occurred during the mean treatment duration of 35 months
(median 33 months, range 28–42 months). In 8 of the 24
patients (33%), the treatment was assessed as ineffective due to
inﬂammatory activity (2 patients), inﬂammatory activity asso-
ciated with development of CMO (3 patients), new-onset CMO
(1 patient) or persistent CMO during the therapy (2 patients).
The mean relapse rate in the entire group of 24 patients was 0.2
relapses per PY (95% CI 0.11 to 0.33).
Table 1 Baseline characteristics of 24 patients with birdshot
chorioretinopathy treated with derivatives of mycophenolic acid
Patient characteristics
Number of patients
or period of time
Mean age at therapy start, (median, range) [years] 51.5 (54.5, 30–71)
Gender, female [n/N (%)] 14/24 (58)
Bilaterality [n/N (%)] 24/24 (100)
Mean duration of disease at therapy start, (median,
range) [months]
29.2 (20, 5–115)
HLA-A29 positive [n/N (%)] 24/24 (100)
Previous treatment [n/N (%)] 14/24 (58)
CS monotherapy 11/24 (46)
1 IS agent (CSA) 1/24 (4)
CS+1 IS agent (AZA, MTX) 2/24 (8)
Reason for initiation of MMF/MPS therapy [n/N (%)]
Activity during CS treatment 5/24 (21)
Activity during previous IS treatment 2/24 (8)
Side effects of previous treatment 1/24 (4)
MMF/MPS as a first IS agent 16/24 (67)
Mean follow-up time (median, range) [months] 43 (33, 12–106)
Mean duration of MMF/MPS therapy
(median, range) [months]
38 (32, 12–79)
AZA, azathioprine; CS, corticosteroids; CSA, cyclosporine A; IS, immunosuppressive
agent; MMF, mycophenolate mofetil; MPS, mycophenolate sodium; MTX,
methotrexate; n, number of affected patients; N, total number of patients.
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We separately analysed the efﬁcacy of each of both derivatives
of MPA. Control of intraocular inﬂammation was achieved in 9
of the 12 patients (75%) treated with MMF and in 7 of the 12
patients (58%) treated with MPS, respectively (Fisher’s exact
test, p=0.67). MMF was assessed as ineffective in three patients
(25%) because of inﬂammatory activity (two patients) or inﬂam-
matory activity with CMO (one patient). MPS was assessed as
ineffective in ﬁve patients (42%) due to inﬂammatory activity
with CMO (two patients), new-onset CMO (one patient) or per-
sistent CMO during the therapy (two patients).
At baseline, CMO was present in seven patients (29%).
During the follow-up, complete resolution of CMO was
observed in ﬁve patients and partial resolution in two patients.
CMO occurred for the ﬁrst time during the MMF/MPS treat-
ment in four patients (17%, rate 0.05/PY).
FA was performed in 22 patients. The angiographic signs of
activity were signiﬁcantly reduced during the follow-up
(p<0.05). FA data are presented in detail in table 2.
Steroid-sparing effect
During the treatment period, 21 patients (88%) received sys-
temic corticosteroids. In 20 of these patients (95%), the corti-
costeroids could be tapered to a daily dose of ≤10 mg (rate
0.26/PY). Corticosteroid tapering to a maintenance dose of
5 mg daily could be achieved in 12 patients (57%, rate 0.16/
PY). Systemic corticosteroids were discontinued in three patients
(14%, rate 0.04/PY).
Development of retinal function
Best-corrected visual acuity
Mean logMAR BCVA did not statistically signiﬁcantly differ
from baseline over the follow-up period (p>0.05, table 3). At
baseline, BCVA of ≤20/40 (logMAR 0.3) in the worse eye was
found in 12 patients (50%), in 3 patients (13%) it was ≤20/200
(logMAR 1). At the end of follow-up, BCVA of ≤20/40
(logMAR 0.3) in the worse eye was observed in 10 patients
(42%), in 2 patients (8%) it was ≤20/200 (logMAR 1).
Visual ﬁeld
A visual ﬁeld examination was performed in 22 patients. The
common observed visual ﬁeld patterns were enlarged blind spot
(20% of eyes), disseminated visual ﬁeld defects (30%), central
and paracentral scotoma (18%) and arcuate visual ﬁeld defects
(14%). In 16% of eyes, no visual ﬁeld defects were found.
In general, the foveal threshold and the number of absolute and
relative visual ﬁeld defects within the central 30° visual ﬁeld did
not differ signiﬁcantly between baseline and follow-up visits
(table 3).
Electroretinography
Full-ﬁeld ERG was performed in 21 patients. None of the ana-
lysed ERG parameters, including amplitudes and implicit times
of the combined rod-cone responses and the light-adapted
30 Hz responses, showed statistically signiﬁcant differences over
the treatment period (p>0.05; data not shown).
Therapy change
The mean duration of MMF/MPS treatment was 38 months
(median 32 months, range 12–79 months). At the end of
follow-up, 15 patients (63%) received MMF or MPS as the only
corticosteroid-sparing agent. In three patients (8%, rate 0.03/
PY), the treatment could be discontinued due to control of
inﬂammation. Therapy change was necessary in seven patients
(29%, rate 0.09/PY): four of these patients received interferon-α
in addition due to refractory CMO, methotrexate was added to
MMF in two patients due to activity of intraocular inﬂammation
and the therapy was switched to adalimumab in one patient due
to inﬂammatory activity with CMO.
Side effects
Drug-related side effects occurred in 12 patients (50%, rate
0.16/PY). Of these, ﬁve patients experienced more than one
adverse effect. The rate of side effects during the treatment was
0.24/PY. The most common side effects were gastrointestinal
discomfort (n=5), increased liver enzymes (n=3), headache and
malaise (n=2), susceptibility to infection (n=2) and skin rash
(n=2). In six patients, a reduction of MMF/MPS was required
due to adverse effects (25%, rate 0.08/PY). In four patients
(17%, rate 0.05/PY), the therapy was switched from MMF to
MPS due to gastrointestinal discomfort. In all four patients, the
gastrointestinal side effects disappeared during MPS treatment.
No severe adverse effects requiring therapy discontinuation
were observed.
DISCUSSION
The treatment of BSCR is a challenge due to its chronic progres-
sive course leading to severe visual impairment. To achieve
inﬂammatory control and preserve vision, early steroid-sparing
treatment is recommended.5 7 19 In this study, we report on the
long-term results with both derivatives of MPA, MMF and
MPS, in the treatment of patients with BSCR. We achieved
Table 2 Fluorescein angiographic parameters in 24 patients with
birdshot chorioretinopathy treated with derivatives of mycophenolic
acid
FA parameters Baseline After 1 year After 2 years Last visit
Optic disc hyperfluorescence [n/N eyes]
Right eyes
No 1/22 0/13 2/16 3/21
Mild 4/22 8/13 12/16 14/21
Strong 17/22 5/13 2/16 4/21
Left eyes
No 1/22 0/13 1/16 2/21
Mild 4/22 8/13 13/16 15/21
Strong 17/22 5/13 2/16 4/21
Comparison with baseline, p value*
Right eyes N/A 0.29 0.012† <0.001†
Left eyes N/A 0.29 0.012† <0.001†
Retinal vascular leakage [n/N eyes]
Right eyes
No 4/22 4/13 8/16 12/21
Mild 4/22 6/13 8/16 8/21
Strong 14/22 3/13 0/16 1/21
Left eyes
No 3/22 4/13 7/16 12/21
Mild 4/22 6/13 9/16 8/21
Strong 15/22 3/13 0/16 1/21
Comparison with baseline, p value*
Right eyes N/A 0.07 0.022† 0.002†
Left eyes N/A 0.07 0.013† 0.001†
*p Values according to the sign test.
†Significant changes are indicated with asterisks.
FA, fluorescein angiography; n, number of affected eyes; N, total number of eyes;
N/A, not applicable.
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control of inﬂammation in 67% of the patients treated with
MMF or MPS. Some previous studies have reported the use of
various immunosuppressive agents, including MMF, in patients
with BSCR.6 7 15 However, the outcome of MMF treatment
was not analysed separately from the other immunosuppressive
drugs. Recently, Cervantes-Castaneda et al20 presented their
results of combined immunosuppressive therapy with cyclospor-
ine A and MMF in patients with BSCR. The authors reported
on the control of inﬂammation in 67.4% of the patients.
However, therapy discontinuation because of side effects was
necessary in 10% of the patients. Because of differences in the
therapy schemata and study aims, the study of
Cervantes-Castaneda et al and our study are not fully compar-
able. Interestingly, we observed a similar efﬁcacy of the BSCR
treatment with only one steroid-sparing agent (MMF or MPS).
Moreover, no severe side effects requiring therapy discontinu-
ation were found in our patients. As a combined therapy with
two immunosuppressive agents may be associated with an
increased risk of malignancies and organ toxicity, we prefer to
initiate treatment with just one steroid-sparing drug. In the case
of inefﬁcacy, therapy with biological agents may be considered.
When analysing the efﬁcacy of MMF and MPS separately, no
signiﬁcant difference in the anti-inﬂammatory potency of both
MPA derivatives was observed. However, in 17% of the
patients, a therapy switch from MMF to MPS was needed
because of gastrointestinal side effects. Gastrointestinal discom-
fort is the most common side effect of MMF, and the necessity
of dose reduction or even discontinuation of the drug may limit
its clinical beneﬁt.9 10 21 In such cases, MPS can be used due to
its superior gastrointestinal side effect proﬁle. A therapy switch
from MMF to MPS has been previously reported in patients
with various inﬂammatory eye diseases.11 12 Our observation
shows that in cases of adverse effects during MMF treatment, a
switch to MPS is also an option in patients with BSCR.
CMO is the most common complication of BSCR and has
been found in up to 84% of the patients suffering from this
disease.1 In our study, we observed a lower incidence of CMO
indicating that the derivatives of MPA have the potential to
reduce the risk of CMO. However, they cannot completely
prevent the occurrence of CMO. A similar observation has been
reported by our own group in patients with chronic non-
infectious uveitis treated with MMF.22
With regards to functional assessment, it is well known that in
BSCR, exclusive BCVA assessment should not be considered as
a reliable parameter for evaluating therapy response.7 20 23 24 In
the present study, BCVA, visual ﬁeld and full-ﬁeld ERG para-
meters remained stable during the treatment and no worsening
of the retinal function was observed. This suggests that MMF
and MPS are effective not only in controlling inﬂammation but
also in the long-term preservation of retinal function.
We are aware of the limitations of our study arising from its
retrospective nature. However, this is the ﬁrst study that has
assessed the efﬁcacy of both derivatives of MPA, MMF and
MPS, in the treatment of BSCR according to standardised
criteria.
In conclusion, MMF and MPS were shown to be effective
and safe steroid-sparing agents in the therapy of BSCR, and we
recommend them as a ﬁrst-line immunosuppressive treatment in
Table 3 Best-corrected visual acuity and visual field parameters at baseline and follow-up in 24 patients with birdshot chorioretinopathy
treated with derivatives of mycophenolic acid
Parameters Baseline After 1 year After 2 years Last visit
BCVA [logMAR]
Right eyes: mean (±SD) 0.25 (±0.25) 0.24 (±0.38) 0.29 (±0.39) 0.19 (±0.31)
Left eyes: mean (±SD) 0.32 (±0.41) 0.37 (±0.51) 0.34 (±0.44) 0.3 (±0.44)
Comparison with baseline, p value*
Right eyes N/A 0.837 1.0 0.245
Left eyes N/A 0.446 0.452 0.835
Foveal threshold [dB]
Right eyes: mean (±SD) 27.2 (±6.7) 29.9 (±4.6) 29.7 (±3.8) 28.5 (±5.9)
Left eyes: mean (±SD) 25.8 (±8.5) 27.4 (±4.9) 26.5 (±7.8) 26.4 (±6.6)
Comparison with baseline, p value*
Right eyes N/A 0.560 0.367 0.370
Left eyes N/A 0.326 0.597 0.908
No. of absolute VFDs within the central 30° visual field [n]
Right eyes: median (IQR) 1.5 (0–4) 2 (0–12) 2 (0–5) 3 (0–10)
Left eyes: median (IQR) 4 (0–14.5) 2.5 (0.3–8.5) 6 (2–10) 4 (2–7)
Comparison with baseline, p value†
Right eyes N/A 0.173 1.0 0.143
Left eyes N/A 0.730 0.611 0.937
No. of relative VFDs within the central 30° visual field [n]
Right eyes: median (IQR) 12 (4.8–38.8) 9 (6.3–12.8) 9 (4–16) 7 (4–19)
Left eyes: median (IQR) 29 (4–38.3) 7 (3.3–24.8) 16 (5–26) 16 (5–27)
Comparison with baseline, p value†
Right eyes N/A 0.126 0.068 0.026‡
Left eyes N/A 0.906 0.327 0.648
*p Values according to paired t test.
†p Values according to the Wilcoxon signed-rank test.
‡Significant changes are indicated with asterisks.
BCVA, best-corrected visual acuity; dB, decibel; logMAR, logarithm of minimum angle of resolution; n, number of VFDs (visual field defects) within the central 30° visual field; N/A, not
applicable; No., number.
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this severe sight-threatening disease. In case of gastrointestinal
side effects during MMF treatment, a therapy switch to MPS
should be performed because of its better gastrointestinal
tolerability.
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